Please assess the completion status of the following clinical trial:

Trial Title: CASTRO1 - Study on CRP Apheresis After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ischaemic stroke with determination of infarct size by imaging (MRI)~* NIHSS 1-24~* CRP increase ≥ 5 mg/l within presumed 72 hours after stroke and/or CRP value \> 10 mg/l~* written informed consent of the patient or his legal representative~Exclusion Criteria:~* age \< 18 years~* Severe dysphagia (danger of aspiration pneumonia)~* Clinical or laboratory evidence of a severe systemic infection~* Participation in other interventional studies~* Contraindications against apheresis therapy~* Modified Rankin Scale (mRS) before index event ≥ 3~* Intracranial hemorrhage~* Epileptic seizure in the context of the acute event~* Pregnancy, lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apheresis group (Type: EXPERIMENTAL): 10 patients receive a maximum of 3 apheresis treatments at intervals of 24 ± 12 hours each (from the beginning of the preceding treatment). The first treatment starts within 72 hours after infarction or, in case of an unclear time window, within presumed 72 hours after the patient was last seen free of symptoms. No further treatments are carried out if the CRP concentration before the start of a treatment is \<10 mg/l or if the patient has been discharged from hospital.~For each treatment, 1.5 - 2.5 times the plasma volume is processed. The duration of each treatment is approximately 4-6 hours.
- Control group (Type: NO_INTERVENTION): 10 patients of the control group receive the same examinations as arm 1 (verum group) but no apheresis treatments after ischemic stroke.

Based on this trial design, predict the completion outcome and termination type (if applicable).